Lymphatic Forum
in Chicago, IL
June 8-10, 20
17
Vasculata 2017
Chicago, IL
July 24-27, 2017
(new dates!)
October 15-19, 2017
20th IVBM
Helsinki, Finland
June 3-7, 2018
|
Diamond Level
Welcome Reception Host
|
|
|
|
Registration Now Open for . . .
|
Vascular Surgery Visiting Professional Program
|
Vascular Surgery Visiting Professional Program for International Clinicians
The Guy's and St Thomas' NHS Foundation Trust Vascular Surgery Visiting Professionals Programme (VPP) is designed to provide international visiting professionals with the opportunity to profit from exposure to cutting edge endovascular case selection, planning, operative technique and new developments in the field. The program's aim is to provide a unique development experience intended to broaden a visiting professional's surgical education and to teach new skills with which the participant can ultimately enhance his/her home institution. The program offers an unrivaled opportunity covering the full range of vascular and endovascular surgery in a high volume, world class vascular unit in the heart of London.
The remit of the Endovascular VPP is to offer focused training in complex endovascular endografting of the full range of aortic pathologies that affect the aorta from the aortic valve to the femoral vessels. In addition, the unit maintains a comprehensive complex open aortic service and VPP participants are encouraged to profit from the learning opportunities that are available in open aortic surgery.
|
The power and pitfalls of public speaking
Andrew Gaudet and Laura Fonken, postdocs at the University of Colorado, Boulder, have produced a
helpful set of tips
to improve the effectiveness of oral presentations. Some of their pieces of advice ("Use your laser pointer effectively") may be traceable to the primordial seminar ("Make sure all the family can see the ground where you are drawing with your stick"), while others are unmistakably modern ("
Use the 'Slide Sorter' PowerPoint view to understand the big picture"). All, however, are valuable and well worth remembering-by first-time and experienced speakers alike.
|
Welcome to our New Members:
Julie Goodwin, Yale University
Mila Romanova, University of Illinois at Chicago
Aimee Vozenilek, Louisiana State University HSC - Shreveport
|
|
Recent Publications by NAVBO Members
|
| The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue
Genes & Development
Noncanonical mechanistic target of rapamycin (mTOR) pathways remain poorly understood. Mutations in the tumor suppressor folliculin (FLCN) cause Birt-Hogg-Dube syndrome, a hamartomatous disease marked by mitochondria-rich kidney tumors. FLCN functionally interacts with mTOR and is expressed in most tissues, but its role in fat has not been explored. Read more Heme oxygenase and carbon monoxide protect from muscle dystrophy
Skeletal Muscle
BACKGROUND: Duchenne muscle dystrophy (DMD) is one of the most common lethal genetic diseases of children worldwide and is 100% fatal. Steroids, the only therapy currently available, are marred by poor efficacy and a high side-effect profile. New therapeutic approaches are urgently needed. Read more Cardiogenic shock in pregnancy: Analysis from the National Inpatient Sample
Hypertension in Pregnancy
OBJECTIVE: Cardiogenic shock (CS) may occur during pregnancy and dramatically worsen peripartum outcomes. Read more β-arrestin is critical for early shear stress-induced Akt/eNOS activation in human vascular endothelial cells
Biochemical and Biophysical Research Communications
Recent evidence suggests that β-arrestins, which are involved in G protein-coupled receptors desensitization, may influence mechanotransduction. Here, we observed that nitric oxide (NO) production was abrogated in human saphenous vein endothelial cells (SVECs) transfected with siRNA against β-arrestin 1 and 2 subjected to shear stress (SS, 15 dynes/cm2, 10 min). Read more Rac2 Modulates Atherosclerotic Calcification by Regulating Macrophage Interleukin-1β Production
Arteriosclerosis, Thrombosis, and Vascular Biology
OBJECTIVE: The calcium composition of atherosclerotic plaque is thought to be associated with increased risk for cardiovascular events, but whether plaque calcium itself is predictive of worsening clinical outcomes remains highly controversial. Inflammation is likely a key mediator of vascular calcification, but immune signaling mechanisms that promote this process are minimally understood. Read more |
The NIH Common Fund Rallies Behind "The Vasculome"
Zorina Galis, PhD, Vascular Biology & Hypertension Branch Chief in the
Division of Cardiovascular Sciences at the NHLBI and an organizer of the "Vasculome" session at IVBM 2016, reports that the
NIH Common Fund
has approved the
Human BioMolecular Atlas Platform
(HuBMAP) for funding in FY2018. Common Fund programs support cross-cutting, trans-NIH programs that require participation by at least two NIH Institutes or Centers or would otherwise benefit from strategic planning and coordination. Specific Funding Opportunity Announcements for HuBMAP, currently under development and inspired in part by the Vasculome proposal, will aim to facilitate research on single cells within human tissues by building a central platform that would bring together data from around the world and make it accessible to the entire scientific community. Learn more about Common Fund initiatives here.
Propranolol approved for angiosarcoma in Europe
The beta-adrenergic antagonist propranolol, frequently prescribed as an antihypertensive, was recently granted Orphan Drug Designation by the European Commission to
treat soft tissue sarcoma
. The cancer affects approximately one quarter of a million people living in Europe, and, according to investigator Brad Bryan, Ph.D., at Texas Tech University, affected patients "...have a very poor survival rate. Four out of 10 patients with the cancer will die and are in urgent need of new treatment options." Dr. Bryan's lab reported the efficacy of propranolol in
attenuation of cutaneous angiosarcoma
.
Whose dime accounts for the lion's share of medical advances?
Thomas Stossel, MD, Professor Emeritus at Harvard Medical School and visiting scholar at the American Enterprise Institute, writes in
The Wall Street Journal
(January 6, 2017) that medical innovations arise principally from work in the private sector rather than through federally-funded academic institutions. His article, "Don't Thank Big Government for Medical Breakthroughs," describes the merit of closer interaction between academia and industry, favoring more directed, goal-oriented research of the basic variety. Stossel expands on these views in
National Affairs
, tempered by the acknowledgement of a need for federal "subsidy" of university basic research and training, although to a more limited extent than currently practiced.
|
|
Job Postings
|
|
Job Title
|
Company
|
Location
|
|
|
University of North Carolina
|
Chapel Hill, NC
|
Postdoctoral Fellow
|
University of Washington
|
Seattle, WA
|
|
|
Stanford School of Medicine
|
Stanford, CA
|
Post Doctoral Fellow
|
Medical College of Wisconsin
|
Milwaukee, WI
|
|
|
University of California, San Francisco
|
San Francisco, CA
|
|
|
Gold Level
Academic Supporter
 |
|
Silver Level Academic Supporters
|
|
|
|
Bronze Level Academic Supporters
|
|
|
